Landscapes / Targets
IL-1β
5 drugs act on IL-1β, in 14 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs5
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Interleukin-1 receptor antagonist |
Approved | — | |||
| Also tested for | Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset | ||||
| Open drug page | |||||
Monoclonal antibody |
AbbVie · Public ABBV |
Phase 3 | Dec 2026Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa, Atopic Dermatitis and 4 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 2 | 22 Apr 2027Phase 2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 22 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Jun 2027Phase 2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Colorectal Cancer Metastatic | ||||
| Open drug page | |||||
— |
3SBio · Public 1530.HK |
Phase 2 | 11 Aug 2027Phase 2 trial completes | ||
| Next date | 11 Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | Gout Arthritis | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 5 of 5 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026